- Conditions
- Breast Cancer, Lobular Carcinoma, Invasive Breast Cancer
- Interventions
- Tissue specimen
- Other
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- Female only
- Enrollment
- 550 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2021
- U.S. locations
- 1
- States / cities
- New York, New York
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 2065–2088
of 11,977
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- LN-145, Durvalumab
- Biological · Drug
- Lead sponsor
- Iovance Biotherapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 8
- States / cities
- La Jolla, California • Los Angeles, California • Louisville, Kentucky + 5 more
- Conditions
- Hepatocellular Carcinoma of the Liver, Subjects Eligible for Liver Transplantation
- Interventions
- Surefire Precision Infusion System
- Device
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 11 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- ALT-803, Nivolumab
- Biological
- Lead sponsor
- Medical University of South Carolina
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 67 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2023
- U.S. locations
- 4
- States / cities
- Weston, Florida • Minneapolis, Minnesota • Cleveland, Ohio + 1 more
- Conditions
- Advanced Adenocarcinoma, Advanced Malignant Solid Neoplasm, Metastatic Adenocarcinoma, Metastatic Malignant Solid Neoplasm, Recurrent Adenocarcinoma, Recurrent Malignant Solid Neoplasm
- Interventions
- Antineoplastic Vaccine, Sargramostim, Pembrolizumab
- Biological
- Lead sponsor
- University of California, Davis
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 77 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2034
- U.S. locations
- 1
- States / cities
- Sacramento, California
- Conditions
- Head and Neck Cancer
- Interventions
- Nivolumab
- Drug
- Lead sponsor
- Trisha Wise-Draper
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2026
- U.S. locations
- 2
- States / cities
- Detroit, Michigan • Cincinnati, Ohio
- Conditions
- Adenocarcinoma of the Lung, Mucinous Adenocarcinoma of the Colon, Mucinous Adenocarcinoma of the Rectum, Signet Ring Adenocarcinoma of the Colon, Signet Ring Adenocarcinoma of the Rectum, Squamous Cell Lung Cancer, Stage I Colon Cancer, Stage I Rectal Cancer, Stage IA Non-small Cell Lung Cancer, Stage IB Non-small Cell Lung Cancer, Stage IIA Colon Cancer, Stage IIA Non-small Cell Lung Cancer, Stage IIA Rectal Cancer, Stage IIB Colon Cancer, Stage IIB Non-small Cell Lung Cancer, Stage IIB Rectal Cancer, Stage IIC Colon Cancer, Stage IIC Rectal Cancer, Stage IIIA Colon Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIA Rectal Cancer, Stage IIIB Colon Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IIIB Rectal Cancer, Stage IIIC Colon Cancer, Stage IIIC Rectal Cancer
- Interventions
- educational intervention, medical chart review
- Other
- Lead sponsor
- Fox Chase Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,440 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Carcinoma, Squamous Cell
- Interventions
- JNJ-90301900 (NBTXR3), Cetuximab, Radiation Therapy
- Drug · Radiation
- Lead sponsor
- Johnson & Johnson Enterprise Innovation Inc.
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 26
- States / cities
- Birmingham, Alabama • Duarte, California • La Jolla, California + 23 more
- Conditions
- Metastatic Urothelial Carcinoma, Urothelial Cancer, Urothelial Carcinoma, Locally Advanced or Metastatic Urothelial Carcinoma, Bladder Cancer, Bladder Neoplasms, Bladder Tumors, Cancer of Bladder, Cancer of the Bladder, Malignant Tumor of Urinary Bladder, Neoplasms, Bladder, Urinary Bladder Cancer
- Interventions
- Not listed
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 5,122 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Lung Carcinoid Tumor, Lung Non-Small Cell Carcinoma, Metastatic Lung Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
- Interventions
- Cone-Beam Computed Tomography, Conventional Surgery, Laser Ablation
- Procedure
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Docetaxel + Plinabulin (DP), Docetaxel (D)
- Drug
- Lead sponsor
- BeyondSpring Pharmaceuticals Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 559 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2023
- U.S. locations
- 19
- States / cities
- Chandler, Arizona • Anaheim, California • Whittier, California + 16 more
- Conditions
- Advanced or Metastatic NSCLC
- Interventions
- Datopotamab deruxtecan, KEYTRUDA®, Carboplatin, Cisplatin
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 145 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 9
- States / cities
- Scottsdale, Arizona • Duarte, California • Washington D.C., District of Columbia + 5 more
- Conditions
- Breast Cancer, Colorectal Cancer, Head and Neck Cancer, Kidney Cancer, Lung Cancer, Pancreatic Cancer, Sarcoma, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- cetuximab, bortezomib
- Biological · Drug
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2010
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Advanced Endometrial Carcinoma, Recurrent Endometrial Carcinoma
- Interventions
- Bevacizumab, Biospecimen Collection, Carboplatin, Computed Tomography, Magnetic Resonance Imaging, Paclitaxel, Pembrolizumab
- Biological · Procedure · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 255 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 311
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 232 more
- Conditions
- Clear Cell Renal Cell Carcinoma, Renal Cell Carcinoma (RCC), Stage II Renal Pelvis Cancer AJCC v8, Stage III Renal Pelvis Cancer AJCC v8
- Interventions
- Pembrolizumab, Tivozanib, Biospecimen Collection, MRI, Computed Tomography, Biopsy, Questionnaire Administration
- Biological · Drug · Procedure + 1 more
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,040 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2037
- U.S. locations
- 429
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Jonesboro, Arkansas + 340 more
- Conditions
- Extensive-stage Small Cell Lung Cancer
- Interventions
- Neoantigen DNA vaccine, Durvalumab, TDS-IM v2.0 Device, Peripheral blood draws
- Biological · Drug · Device + 1 more
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2029
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage II Pancreatic Cancer, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer
- Interventions
- 7-hydroxystaurosporine, gemcitabine hydrochloride, pharmacological study, laboratory biomarker analysis
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2002
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Lung Carcinoma
- Interventions
- Electronic Health Record Review, Transbronchial Cryobiopsy Guided by Three-Dimensional Fluoroscopy
- Other · Procedure
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Prostate Carcinoma
- Interventions
- Placebo Administration, Quality-of-Life Assessment, Questionnaire Administration, Sinecatechins
- Drug · Other
- Lead sponsor
- ECOG-ACRIN Cancer Research Group
- Network
- Eligibility
- 21 Years and older
- Enrollment
- 360 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 345
- States / cities
- Fairbanks, Alaska • Phoenix, Arizona • Fayetteville, Arkansas + 224 more
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Hypofractionated Stereotactic Boost, Carboplatin, Paclitaxel, Image-guided IMRT
- Radiation · Drug
- Lead sponsor
- West Virginia University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 1
- States / cities
- Morgantown, West Virginia
- Conditions
- Advanced Solid Tumors
- Interventions
- BGB-30813, Tislelizumab
- Drug
- Lead sponsor
- BeiGene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 3
- States / cities
- Hackensack, New Jersey • Houston, Texas • San Antonio, Texas
- Conditions
- HCC - Hepatocellular Carcinoma
- Interventions
- Yttrium-90 Radiation Segmentectomy (Y90 RS) using glass microspheres
- Other
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Squamous Non-Small Cell Lung Cancer
- Interventions
- Carboplatin, Veliparib, Paclitaxel, Placebo to veliparib
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 970 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 38
- States / cities
- Jonesboro, Arkansas • Los Angeles, California • Aurora, Colorado + 30 more
- Conditions
- Metastatic Melanoma, Head Neck Cancer
- Interventions
- SD-101(1), Pembrolizumab, SD-101(2), SD-101(3)
- Drug · Biological
- Lead sponsor
- Dynavax Technologies Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 241 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 30
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 26 more